Incremental hemodialysis for patients with end-stage renal disease
Official title: RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis
Run by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · NCT04360694 · Data updated 2026-11-12
This study is testing if a new way of doing hemodialysis, which adjusts treatment based on how well your kidneys still work, can help people with end-stage renal disease feel better and stay healthier compared to the usual treatment schedule.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 190 (estimated) |
| Sponsor | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari Academic / other |
| Locations | 1 site (Bari) |
| Status | Recruiting |
| Started | May 10, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 12, 2024 |
| Trial ID | NCT04360694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who are starting or have recently started maintenance hemodialysis due to advanced chronic kidney disease.
✕Probably not a fit
Patients with acute kidney injury, those with a glomerular filtration rate above 10 mL/min/1.73 m2, or those already receiving other forms of dialysis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the efficacy and safety of incremental hemodialysis compared to the standard thrice-weekly hemodialysis regimen for patients with end-stage renal disease. The study utilizes a Variable Target Model that adjusts dialysis frequency based on residual kidney function, allowing for potentially less frequent treatments. It is a pragmatic, multicenter, open-label randomized controlled trial designed to assess various outcomes, including kidney function preservation and cardiovascular health. The trial aims to provide clearer standards for incorporating residual kidney function into dialysis treatment plans.
Why it matters
Potential benefit: If successful, this approach could lead to improved kidney function preservation and better overall health outcomes for patients on hemodialysis.
How similar studies have gone: While observational studies have shown promise for incremental hemodialysis, this randomized controlled trial is among the first to rigorously test this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged \> 18 years * Start of maintenance hemodialysis treatment due to advanced CKD stage 5D * Patients who are about to start HD or have already started HD within a period of ≤ 2 weeks * Glomerular filtration rate \<= 10 mL/min/1.73 m2, as estimated by means of CKD-EPI formula. Exclusion Criteria: * Age \< 18 years * Acute kidney injury or acute on chronic kidney injury * eGFR higher than 10 mL/min/1.73 m2 * UO \< 600 mL/day * Already treated with other replacement therapies (peritoneal dialysis or kidney transplant) * Unable or unwilling to give informed consent. * Unable to comply with trial procedures, e.g., collection of UO. * Likely survival prognosis or planned modality or centre transfer \< 6 months. * Patients who are in the waiting list for a living kidney transplant * Associated diseases: active neoplastic disease; refractory congestive heart failure (type IV NYHA, ejection fraction ≤ 30%) requiring high ultrafiltration volumes per session.
Where it's running
-
Azienda Ospedaliero Universitaria Consorziale Policlinico
Bari, Italy Recruiting
Study contacts
- Study coordinator: Loreto Gesualdo, MD
- Email: loreto.gesualdo@uniba.it
- Phone: +390805594041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How the body handles fosmanogepix in adults on dialysis
This study tests how fosmanogepix behaves in the body and its safety in adults with end-stage kidney disease on dialysis, compared to people with normal kidney function.
-
Coated Aldehyde Oxystarch to lower PBUTs in adults on dialysis
This study tests whether a coated oral adsorbent called Coated Aldehyde Oxystarch (Xiqing) can lower protein-bound uremic toxins in adults on maintenance dialysis and checks its safety.
-
Changes in regional ventilation-perfusion after artery graft ballooning in dialysis patients
This study tests how the lungs' ventilation and blood flow respond right before, during, and after repairing an arteriovenous graft with balloon angioplasty in adults on dialysis.
-
Four-hour pHA130 hemoadsorption with hemodialysis
We will test whether using pHA130 hemoadsorption for 4 hours instead of 2 during regular dialysis removes more protein-bound toxins like indoxyl sulfate in people on maintenance hemodialysis.
-
CRISPR-edited donor kidney transplant to reduce rejection risk
This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.
-
Progressive muscle relaxation plus walking to reduce fatigue in adults on dialysis
This program will try progressive muscle relaxation combined with regular walking to see if it reduces fatigue for adults receiving in-center hemodialysis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.